EMR vs XYL

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 12, 2026

EMR

53.3
AI Score
VS
EMR Wins

XYL

40.5
AI Score

Investment Advisor Scores

EMR

53score
Recommendation
HOLD

XYL

41score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric EMR XYL Winner
Revenue 4.87B 6.66B XYL
Net Income 720.00M 747.00M XYL
Gross Margin 54.5% 40.1% EMR
Net Margin 14.8% 11.2% EMR
ROE 3.5% 7.3% XYL
ROA 1.7% 4.3% XYL
Total Assets 42.21B 17.33B EMR
Debt/Equity 0.37 0.29 XYL
Current Ratio 0.90 1.39 XYL

Relative Price Performance (Last 90 Days)

EMR 1M: +2.2% · 3M: +1.7% XYL 1M: -7.2% · 3M: -21.0%

Current Technical Phase

EMR

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (1.6% over 20 days), RSI 55

RSI (14): 55.2 · Price: $167.06

XYL

Markdown
Sell / avoid

Price below a falling SMA50 (slope -6.0%), weak momentum, RSI 41

RSI (14): 41.4 · Price: $95.11

Fundamentals Snapshot

Metric EMR XYL
Market Cap — —
Forward P/E 23.1 16.2
Trailing P/E 35.0 21.5
Revenue (TTM) — —
Revenue Growth 0.1% 0.0%
Gross Margin 0.5% 0.4%
Operating Margin 0.3% 0.2%
EPS 4.79 4.51
Dividend Yield 0.00% 0.02%

Frequently Asked Questions

Based on our detailed analysis, EMR is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.